MedDataX Logo

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

NCT ID: NCT04799990

Last Updated: 2022-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-23

Study Completion Date

2022-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study is not recruiting and using secondary data sources only

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02203851

Psoriasis
COMPLETED PHASE2

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

NCT05969223

Genital Psoriasis Scalp Psoriasis
COMPLETED PHASE4

High Dose Risankizumab for Psoriasis

NCT05283135

Psoriasis
COMPLETED PHASE2

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475

Psoriasis
COMPLETED PHASE4

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

NCT04435600

Psoriasis
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study is not recruiting and using secondary data sources only

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Risankizumab

Participants will receive risankizumab as prescribed by their physician.

Risankizumab

Intervention Type DRUG

Subcutaneous Injection

Comparator Group 1

Participants will receive biologics other than interleukin (IL)-23 antagonists as prescribed by their physician.

Comparator 1

Intervention Type BIOLOGICAL

Subcutaneous or Intravenous Injection

Comparator Group 2

Participants will receive non-biologic systemic small molecules as prescribed by their physician.

Comparator 2

Intervention Type DRUG

Oral, Opthalmic, Subcutaneous or Intravenous Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Risankizumab

Subcutaneous Injection

Intervention Type DRUG

Comparator 1

Subcutaneous or Intravenous Injection

Intervention Type BIOLOGICAL

Comparator 2

Oral, Opthalmic, Subcutaneous or Intravenous Injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Skyrizi

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Study is not recruiting and using secondary data sources only
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P16-772

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
NCT03875482 COMPLETED PHASE3
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT03022045 COMPLETED PHASE3
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03000075 COMPLETED PHASE2
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
NCT04818385 COMPLETED
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT03926169 COMPLETED PHASE2
Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care
NCT04780516 ACTIVE_NOT_RECRUITING
Risankizumab Long-term Remission Study
NCT04630652 ACTIVE_NOT_RECRUITING PHASE4
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
NCT02672852 COMPLETED PHASE3
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
NCT04862286 ACTIVE_NOT_RECRUITING PHASE3
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02694523 COMPLETED PHASE3
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
NCT06333860 ACTIVE_NOT_RECRUITING PHASE4
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
NCT04713592 COMPLETED PHASE3
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03982394 COMPLETED
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148 ACTIVE_NOT_RECRUITING PHASE3
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
NCT02719171 COMPLETED PHASE2
Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation
NCT03518047 COMPLETED PHASE3
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
NCT03875508 COMPLETED PHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308 ACTIVE_NOT_RECRUITING PHASE3
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
NCT06764693 RECRUITING
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
NCT04102007 COMPLETED PHASE3
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
NCT04722640 UNKNOWN PHASE4
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
NCT03478787 COMPLETED PHASE3
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
NCT04433442 COMPLETED
Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece
NCT06247319 ACTIVE_NOT_RECRUITING
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
NCT03047395 COMPLETED PHASE3